Skip to main content
Ambrosia Ventures

Deal Benchmark Data

300+ data pages covering every therapeutic area, clinical phase, and territory combination. Upfront payments, total deal values, royalty rates, and comparable transactions — all in one place.

Oncology

30 benchmark pages · median upfront $3M – $2.1B

Preclinical$32M

Global territory

Preclinical$18M

US Only territory

Preclinical$15M

Ex-US territory

Preclinical$8M

Europe territory

Preclinical$3M

Japan territory

Preclinical$4M

China territory

Phase 1$90M

Global territory

Phase 1$49M

US Only territory

Phase 1$40M

Ex-US territory

Phase 1$22M

Europe territory

Phase 1$8M

Japan territory

Phase 1$11M

China territory

Phase 2$258M

Global territory

Phase 2$142M

US Only territory

Phase 2$116M

Ex-US territory

Phase 2$64M

Europe territory

Phase 2$23M

Japan territory

Phase 2$31M

China territory

Phase 3$721M

Global territory

Phase 3$397M

US Only territory

Phase 3$324M

Ex-US territory

Phase 3$180M

Europe territory

Phase 3$65M

Japan territory

Phase 3$87M

China territory

Approved$2.1B

Global territory

Approved$1.1B

US Only territory

Approved$934M

Ex-US territory

Approved$519M

Europe territory

Approved$187M

Japan territory

Approved$249M

China territory

Neurology/CNS

30 benchmark pages · median upfront $3M – $1.5B

Preclinical$32M

Global territory

Preclinical$18M

US Only territory

Preclinical$15M

Ex-US territory

Preclinical$8M

Europe territory

Preclinical$3M

Japan territory

Preclinical$4M

China territory

Phase 1$76M

Global territory

Phase 1$42M

US Only territory

Phase 1$34M

Ex-US territory

Phase 1$19M

Europe territory

Phase 1$7M

Japan territory

Phase 1$9M

China territory

Phase 2$232M

Global territory

Phase 2$128M

US Only territory

Phase 2$105M

Ex-US territory

Phase 2$58M

Europe territory

Phase 2$21M

Japan territory

Phase 2$28M

China territory

Phase 3$515M

Global territory

Phase 3$283M

US Only territory

Phase 3$232M

Ex-US territory

Phase 3$129M

Europe territory

Phase 3$46M

Japan territory

Phase 3$62M

China territory

Approved$1.5B

Global territory

Approved$812M

US Only territory

Approved$664M

Ex-US territory

Approved$369M

Europe territory

Approved$133M

Japan territory

Approved$177M

China territory

Immunology

30 benchmark pages · median upfront $6M – $3.4B

Preclinical$72M

Global territory

Preclinical$39M

US Only territory

Preclinical$32M

Ex-US territory

Preclinical$18M

Europe territory

Preclinical$6M

Japan territory

Preclinical$9M

China territory

Phase 1$163M

Global territory

Phase 1$90M

US Only territory

Phase 1$74M

Ex-US territory

Phase 1$41M

Europe territory

Phase 1$15M

Japan territory

Phase 1$20M

China territory

Phase 2$547M

Global territory

Phase 2$301M

US Only territory

Phase 2$246M

Ex-US territory

Phase 2$137M

Europe territory

Phase 2$49M

Japan territory

Phase 2$66M

China territory

Phase 3$901M

Global territory

Phase 3$495M

US Only territory

Phase 3$406M

Ex-US territory

Phase 3$225M

Europe territory

Phase 3$81M

Japan territory

Phase 3$108M

China territory

Approved$3.4B

Global territory

Approved$1.9B

US Only territory

Approved$1.5B

Ex-US territory

Approved$854M

Europe territory

Approved$308M

Japan territory

Approved$410M

China territory

Metabolic/Obesity

30 benchmark pages · median upfront $7M – $3.5B

Preclinical$77M

Global territory

Preclinical$43M

US Only territory

Preclinical$35M

Ex-US territory

Preclinical$19M

Europe territory

Preclinical$7M

Japan territory

Preclinical$9M

China territory

Phase 1$229M

Global territory

Phase 1$126M

US Only territory

Phase 1$103M

Ex-US territory

Phase 1$57M

Europe territory

Phase 1$21M

Japan territory

Phase 1$27M

China territory

Phase 2$589M

Global territory

Phase 2$324M

US Only territory

Phase 2$265M

Ex-US territory

Phase 2$147M

Europe territory

Phase 2$53M

Japan territory

Phase 2$71M

China territory

Phase 3$1.2B

Global territory

Phase 3$678M

US Only territory

Phase 3$554M

Ex-US territory

Phase 3$308M

Europe territory

Phase 3$111M

Japan territory

Phase 3$148M

China territory

Approved$3.5B

Global territory

Approved$1.9B

US Only territory

Approved$1.6B

Ex-US territory

Approved$871M

Europe territory

Approved$314M

Japan territory

Approved$418M

China territory

Cardiovascular

30 benchmark pages · median upfront $5M – $3.8B

Preclinical$51M

Global territory

Preclinical$28M

US Only territory

Preclinical$23M

Ex-US territory

Preclinical$13M

Europe territory

Preclinical$5M

Japan territory

Preclinical$6M

China territory

Phase 1$131M

Global territory

Phase 1$72M

US Only territory

Phase 1$59M

Ex-US territory

Phase 1$33M

Europe territory

Phase 1$12M

Japan territory

Phase 1$16M

China territory

Phase 2$505M

Global territory

Phase 2$278M

US Only territory

Phase 2$227M

Ex-US territory

Phase 2$126M

Europe territory

Phase 2$46M

Japan territory

Phase 2$61M

China territory

Phase 3$1.4B

Global territory

Phase 3$759M

US Only territory

Phase 3$621M

Ex-US territory

Phase 3$345M

Europe territory

Phase 3$124M

Japan territory

Phase 3$165M

China territory

Approved$3.8B

Global territory

Approved$2.1B

US Only territory

Approved$1.7B

Ex-US territory

Approved$946M

Europe territory

Approved$340M

Japan territory

Approved$454M

China territory

Infectious Disease

30 benchmark pages · median upfront $6M – $3.6B

Preclinical$65M

Global territory

Preclinical$36M

US Only territory

Preclinical$29M

Ex-US territory

Preclinical$16M

Europe territory

Preclinical$6M

Japan territory

Preclinical$8M

China territory

Phase 1$165M

Global territory

Phase 1$91M

US Only territory

Phase 1$74M

Ex-US territory

Phase 1$41M

Europe territory

Phase 1$15M

Japan territory

Phase 1$20M

China territory

Phase 2$513M

Global territory

Phase 2$282M

US Only territory

Phase 2$231M

Ex-US territory

Phase 2$128M

Europe territory

Phase 2$46M

Japan territory

Phase 2$61M

China territory

Phase 3$1.3B

Global territory

Phase 3$701M

US Only territory

Phase 3$573M

Ex-US territory

Phase 3$318M

Europe territory

Phase 3$115M

Japan territory

Phase 3$153M

China territory

Approved$3.6B

Global territory

Approved$2.0B

US Only territory

Approved$1.6B

Ex-US territory

Approved$906M

Europe territory

Approved$326M

Japan territory

Approved$435M

China territory

Ophthalmology

30 benchmark pages · median upfront $5M – $3.5B

Preclinical$58M

Global territory

Preclinical$32M

US Only territory

Preclinical$26M

Ex-US territory

Preclinical$15M

Europe territory

Preclinical$5M

Japan territory

Preclinical$7M

China territory

Phase 1$158M

Global territory

Phase 1$87M

US Only territory

Phase 1$71M

Ex-US territory

Phase 1$39M

Europe territory

Phase 1$14M

Japan territory

Phase 1$19M

China territory

Phase 2$496M

Global territory

Phase 2$273M

US Only territory

Phase 2$223M

Ex-US territory

Phase 2$124M

Europe territory

Phase 2$45M

Japan territory

Phase 2$60M

China territory

Phase 3$1.4B

Global territory

Phase 3$749M

US Only territory

Phase 3$613M

Ex-US territory

Phase 3$340M

Europe territory

Phase 3$123M

Japan territory

Phase 3$163M

China territory

Approved$3.5B

Global territory

Approved$1.9B

US Only territory

Approved$1.6B

Ex-US territory

Approved$882M

Europe territory

Approved$317M

Japan territory

Approved$423M

China territory

Women's Health

30 benchmark pages · median upfront $3M – $2.4B

Preclinical$38M

Global territory

Preclinical$21M

US Only territory

Preclinical$17M

Ex-US territory

Preclinical$10M

Europe territory

Preclinical$3M

Japan territory

Preclinical$5M

China territory

Phase 1$93M

Global territory

Phase 1$51M

US Only territory

Phase 1$42M

Ex-US territory

Phase 1$23M

Europe territory

Phase 1$8M

Japan territory

Phase 1$11M

China territory

Phase 2$326M

Global territory

Phase 2$179M

US Only territory

Phase 2$147M

Ex-US territory

Phase 2$82M

Europe territory

Phase 2$29M

Japan territory

Phase 2$39M

China territory

Phase 3$865M

Global territory

Phase 3$475M

US Only territory

Phase 3$389M

Ex-US territory

Phase 3$216M

Europe territory

Phase 3$78M

Japan territory

Phase 3$104M

China territory

Approved$2.4B

Global territory

Approved$1.3B

US Only territory

Approved$1.1B

Ex-US territory

Approved$597M

Europe territory

Approved$215M

Japan territory

Approved$286M

China territory

Rare Disease

30 benchmark pages · median upfront $4M – $3.4B

Preclinical$48M

Global territory

Preclinical$26M

US Only territory

Preclinical$22M

Ex-US territory

Preclinical$12M

Europe territory

Preclinical$4M

Japan territory

Preclinical$6M

China territory

Phase 1$120M

Global territory

Phase 1$66M

US Only territory

Phase 1$54M

Ex-US territory

Phase 1$30M

Europe territory

Phase 1$11M

Japan territory

Phase 1$14M

China territory

Phase 2$375M

Global territory

Phase 2$206M

US Only territory

Phase 2$169M

Ex-US territory

Phase 2$94M

Europe territory

Phase 2$34M

Japan territory

Phase 2$45M

China territory

Phase 3$1.3B

Global territory

Phase 3$703M

US Only territory

Phase 3$575M

Ex-US territory

Phase 3$320M

Europe territory

Phase 3$115M

Japan territory

Phase 3$153M

China territory

Approved$3.4B

Global territory

Approved$1.9B

US Only territory

Approved$1.5B

Ex-US territory

Approved$846M

Europe territory

Approved$305M

Japan territory

Approved$406M

China territory

Hematology

30 benchmark pages · median upfront $7M – $5.3B

Preclinical$78M

Global territory

Preclinical$43M

US Only territory

Preclinical$35M

Ex-US territory

Preclinical$19M

Europe territory

Preclinical$7M

Japan territory

Preclinical$9M

China territory

Phase 1$203M

Global territory

Phase 1$112M

US Only territory

Phase 1$91M

Ex-US territory

Phase 1$51M

Europe territory

Phase 1$18M

Japan territory

Phase 1$24M

China territory

Phase 2$612M

Global territory

Phase 2$337M

US Only territory

Phase 2$275M

Ex-US territory

Phase 2$153M

Europe territory

Phase 2$55M

Japan territory

Phase 2$74M

China territory

Phase 3$2.0B

Global territory

Phase 3$1.1B

US Only territory

Phase 3$907M

Ex-US territory

Phase 3$504M

Europe territory

Phase 3$181M

Japan territory

Phase 3$242M

China territory

Approved$5.3B

Global territory

Approved$2.9B

US Only territory

Approved$2.4B

Ex-US territory

Approved$1.3B

Europe territory

Approved$475M

Japan territory

Approved$634M

China territory

Dermatology

30 benchmark pages · median upfront $3M – $3.4B

Preclinical$37M

Global territory

Preclinical$20M

US Only territory

Preclinical$17M

Ex-US territory

Preclinical$9M

Europe territory

Preclinical$3M

Japan territory

Preclinical$4M

China territory

Phase 1$100M

Global territory

Phase 1$55M

US Only territory

Phase 1$45M

Ex-US territory

Phase 1$25M

Europe territory

Phase 1$9M

Japan territory

Phase 1$12M

China territory

Phase 2$375M

Global territory

Phase 2$206M

US Only territory

Phase 2$169M

Ex-US territory

Phase 2$94M

Europe territory

Phase 2$34M

Japan territory

Phase 2$45M

China territory

Phase 3$1.3B

Global territory

Phase 3$688M

US Only territory

Phase 3$563M

Ex-US territory

Phase 3$313M

Europe territory

Phase 3$113M

Japan territory

Phase 3$150M

China territory

Approved$3.4B

Global territory

Approved$1.8B

US Only territory

Approved$1.5B

Ex-US territory

Approved$838M

Europe territory

Approved$302M

Japan territory

Approved$402M

China territory

Gastroenterology

30 benchmark pages · median upfront $5M – $4.0B

Preclinical$51M

Global territory

Preclinical$28M

US Only territory

Preclinical$23M

Ex-US territory

Preclinical$13M

Europe territory

Preclinical$5M

Japan territory

Preclinical$6M

China territory

Phase 1$134M

Global territory

Phase 1$74M

US Only territory

Phase 1$60M

Ex-US territory

Phase 1$34M

Europe territory

Phase 1$12M

Japan territory

Phase 1$16M

China territory

Phase 2$485M

Global territory

Phase 2$267M

US Only territory

Phase 2$218M

Ex-US territory

Phase 2$121M

Europe territory

Phase 2$44M

Japan territory

Phase 2$58M

China territory

Phase 3$1.5B

Global territory

Phase 3$847M

US Only territory

Phase 3$693M

Ex-US territory

Phase 3$385M

Europe territory

Phase 3$139M

Japan territory

Phase 3$185M

China territory

Approved$4.0B

Global territory

Approved$2.2B

US Only territory

Approved$1.8B

Ex-US territory

Approved$990M

Europe territory

Approved$357M

Japan territory

Approved$475M

China territory

Benchmarks powered by 1,400+ primary-sourced biopharma licensing deals

Try Solidus →